Working… Menu

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02277717
Recruitment Status : Completed
First Posted : October 29, 2014
Last Update Posted : July 15, 2020
Information provided by (Responsible Party):
Byondis B.V.

Brief Summary:
The purpose of this study is to evaluate the safety of a new medicinal drug SYD985 at different dose levels in patients with cancer, to understand how SYD985 is handled by the body and to evaluate the effect of SYD985 on the cancer.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: SYD985 (trastuzumab vc-seco-DUBA) Phase 1

Detailed Description:

Cancer cells can have different kinds of proteins on their cell surface; one of these is the protein HER2. HER2 plays an important role in the development of cancer. High expression of HER2 is related to poor prognosis. Although several cancer drugs are available that work via the HER2 protein, a substantial portion of these patients still does not benefit from these treatments.

The new cancer drug SYD985 is being developed by Synthon Biopharmaceuticals B.V. SYD985 is an antibody-drug conjugate and consists of two parts: an antibody and a linker-drug moiety containing a toxin. The antibody part binds to HER2 on the surface of the cancer cell. When SYD985 binds to this cancer cell, it will be internalized by the cell. After proteolytic cleavage of the linker, the toxin will be split off in the cell and the cancer cell will be killed. Thus, SYD985 can be considered as a form of targeted chemotherapy.

This is the first study in which SYD985 is administered to humans. The study consists of two parts:

Part I is the dose-escalation part in which a low dose of SYD985 is given to three cancer patients. If it is well tolerated, a higher dose of SYD985 will be given to 3 other cancer patients. This will continue until a further dose increase is not safe anymore.

In Part II of the study, several groups of patients with a specific type of cancer will receive the SYD985 dose which has been selected for further evaluation.

All patients from both parts of the study will receive SYD985 infusions every three weeks until progression of the cancer or unacceptable toxicity develops.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 185 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : October 2014
Actual Primary Completion Date : January 2019
Actual Study Completion Date : October 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: SYD985 (trastuzumab vc-seco-DUBA)
HER2-targeting Antibody-Drug Conjugate
Drug: SYD985 (trastuzumab vc-seco-DUBA)
IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.

Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities [ Time Frame: 21 days ]
    first cycle

Secondary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: up to 2 years ]
  2. Area under the plasma concentration versus time curve (AUC) of SYD985 [ Time Frame: Baseline, Days 1,2,3,4,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 2 years ]
  3. Peak plasma concentration of SYD985 [ Time Frame: Baseline, Days 1,2,3,4,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 2 years ]
  4. Change from baseline in hematology and blood chemistry parameters [ Time Frame: Baseline and every cycle up to 2 years ]
  5. Number of patients with antibodies against SYD985 [ Time Frame: Baseline and every cycle up to 2 years ]
  6. Objective response rate [ Time Frame: Baseline and every two cycles up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  1. Patient with histologically-confirmed, locally advanced or metastatic tumor who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:

    • Part I: solid tumors of any origin;
    • Part II: breast, gastric, urothelial and endometrial tumors;
  2. For Part II: HER2 tumor status as defined in the protocol;
  3. ECOG performance status ≤ 1;
  4. Life expectancy > 12 weeks;
  5. Adequate organ function;
  6. For Part II: measurable disease.

Main Exclusion Criteria:

  1. Anthracycline treatment within 3 months and/or abnormal cardiac biomarker values;
  2. Other anticancer therapy (except for LHRH agonists) within 4 weeks (6 weeks for nitrosoureas and mitomycin C);
  3. History of infusion-related reactions and/or hypersensitivity to trastuzumab or (ado-) trastuzumab emtansine;
  4. Severe, uncontrolled systemic disease;
  5. LVEF < 55%, or a history of absolute decrease in LVEF of ≥ 10% points to < 50% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine, or a history of decrease in LVEF to < 40% during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;
  6. History of clinically significant CV disease;
  7. Symptomatic brain metastasis, or therapy for brain metastasis (excluding PCI and dexamethasone treatment with stable or decreasing daily dose) within 4 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02277717

Layout table for location information
Antwerp, Belgium
Institut Jules Bordet
Brussels, Belgium
Gent, Belgium
Amsterdam, Netherlands
Groningen, Netherlands
Radboud UMC
Nijmegen, Netherlands
Rotterdam, Netherlands
Institut Catala d'Oncologia
Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Spain
Madrid, Spain
Madrid, Spain
United Kingdom
Beatson Institute for Cancer Research
Glasgow, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Royal Marsden / Institute of Cancer Research
Sutton, United Kingdom
Sponsors and Collaborators
Byondis B.V.
Layout table for investigator information
Study Director: Ellen Mommers, PhD Synthon Biopharmaceuticals B.V., The Netherlands
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Byondis B.V. Identifier: NCT02277717    
Other Study ID Numbers: SYD985.001
First Posted: October 29, 2014    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Byondis B.V.:
antibody-drug conjugate
trastuzumab vc-seco-DUBA
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents